Last reviewed · How we verify
Td
Td is a toxoid vaccine that provides active immunization against tetanus and diphtheria by stimulating antibody production against inactivated bacterial toxins.
Td is a toxoid vaccine that provides active immunization against tetanus and diphtheria by stimulating antibody production against inactivated bacterial toxins. Used for Active immunization against tetanus and diphtheria in adolescents and adults, Booster vaccination in previously immunized individuals.
At a glance
| Generic name | Td |
|---|---|
| Also known as | Tetanus and Diphtheria Toxoid, Td toxoid, Td pre-conditioning, Tetanus-diphtheria (Td) toxoid, Diphtheria and tetanus toxoids, adsorbed |
| Sponsor | University of Florida |
| Drug class | Toxoid vaccine |
| Target | Tetanus toxin (tetanospasmin) and diphtheria toxin |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Td contains inactivated toxins (toxoids) from Clostridium tetani and Corynebacterium diphtheriae. When administered, these toxoids trigger the immune system to produce antibodies and cellular immunity against tetanus and diphtheria toxins, providing protection against these potentially fatal bacterial infections. Td is typically used as a booster vaccine in adolescents and adults who have completed primary immunization series.
Approved indications
- Active immunization against tetanus and diphtheria in adolescents and adults
- Booster vaccination in previously immunized individuals
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Headache
Key clinical trials
- Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS) (NA)
- A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia (PHASE2)
- Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma (PHASE1, PHASE2)
- The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial. (NA)
- Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults (NA)
- Research on Speech Development Trajectories and Predictive Models in Children With Autism Spectrum Disorder
- A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma (PHASE1)
- A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |